tradingkey.logo
tradingkey.logo

Cogent Biosciences' Q2 net loss widens as costs mount

ReutersAug 5, 2025 12:14 PM


Overview

  • Cogent Q2 net loss widens to $73.5 mln from nearly $59.0 mln yr ago

  • Bezuclastinib shows statistically significant results in SUMMIT trial

  • Co's cash position expected to fund operations through 2027, including launch


Outlook

  • Company projects cash runway into 2027


Result Drivers

  • R&D COSTS: R&D expenses increase mainly due to costs incurred to support on-going SUMMIT, PEAK and APEX clinical trials

  • FINANCIAL POSITION - Cogent's cash position, strengthened by a recent public offering, is expected to support operations through 2027


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Net Income

-$73.53 mln

Q2 Income from Operations

-$75.58 mln

Q2 Operating Expenses

$75.58 mln

Press Release: ID:nGNX6VtWgC

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI